Oleg Uritsky
Angel Investor
Boston, United States
Oleg Uritsky is a seed investor in Boston focused on Biotechnology and Medical Device. Oleg Uritsky - Founder & CEO @ Helge Capital, Inc.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Oleg Uritsky invests in
Stages Oleg Uritsky invests in
Countries Oleg Uritsky invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $515k–$1.7M
Investment Focus
Industry
- Biotechnology 6 (35%)
- Medical Device 5 (29%)
- Software 4 (24%)
- Health Care 3 (18%)
- Analytics 2 (12%)
Stage
- Seed 6 (35%)
- Funding Round 4 (24%)
- Convertible Note 4 (24%)
- Series A 3 (18%)
Country
- United States 15 (88%)
- Canada 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Skulpt scans individual muscles to identify strengths and weaknesses and then tailors training for optimal athletic performance. | $1.7M / Seed / Apr 29, 2014 | ||
| Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, isa novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study. | $6.3M / Apr 28, 2014 | ||
| SeniorQuote Insurance Services was founded over 10 years ago by Bill Haynor, a pioneer in offering affordable life and health insurance solutions to the “Baby Boomer” generation. “The desire to protect seniors like me from the uncertainties of life,” Bill explains simply. “That was my reason for starting SeniorQuote.” Bill personally understandsthe importance of having good health coverage at an affordable price. Not long ago, Bill experienced a series of health issues that forced him to rely on his personal Medicare Supplement Insurance. With heart surgery, emergency appendicitis, open-heart surgery, and knee surgery all in a two year period, Bill quickly exceeded his Medicare coverage, with bills totaling well over $400,000. Click for a look at Bill’s medical bill. “It was unbelievable!” Bill laughs. “I have been so healthy for my whole life, but in that short period of time I was hit from every direction, and I would have had to pay almost half a million dollars in medical bills if I didn’t have Medicare and my Medicare Supplement Insurance plan. Instead, I paid nearly nothing. More than ever before, I see the value we provide to our customers at SeniorQuote.” In the early 1970s, Bill worked with the Waddell and Reed life insurance model which promoted low-cost term life insurance in place of higher cost whole life insurance with the proposition that the difference in premium (premium savings) should be invested in mutual funds for retirement. In the 1980s, Bill was a founder of SelectQuote Insurance Services, one of the first life insurance agencies to offer a term life insurance quote comparison service. The SelectQuote service was designed to assist people by providing affordable rates available from highly-rated life insurance companies. In the 1990s, Bill was a founder of First Union Insurance Services, which offered affordable term life and permanent insurance to support the needs of the bank’s many customers. For the past ten years, Bill has keenly focused on the needs of Baby Boomers; helping them to replace their term life insurance with affordable permanent life insurance, and helping them sort through their Medicare and Medicare Supplement options as they approach the mandatory Medicare age of 65. A senior himself, Bill has become an advocate for seniors. Through SeniorQuote, Bill leads his experienced team of insurance professionals to search for healthcare coverage that fits the specific needs of his customers. | Series A / Mar 25, 2014 | ||
| NBD develops coatings and additives to modify surface wetting properties. NBD focuses on coatings and additives that modify surface wettability. NBD's broad product portfolio can influence surface properties for glass and plastic materials to create ultra-durable and functional surface wetting properties.It was founded in 2012 andheadquartered in Brighton, Massachusetts. | Convertible Note / Nov 11, 2013 | ||
| ApplyKit helps manage the college application process from start to finish. Students can take advantage of scholarship offers, a personalized cloud-based suite of tools, and all the additional resources (test prep, tutoring, athletic support) at their fingertips.Partners include: BenchPrep, Veritas Prep, Revolution Prep, Tutor.com, CollegeProwler, Zinch; and non-profit organizations: OneGoal Chicago, Boston Mayor's Youth Line, MindsMatter, and the Chicago Public School system. Launched in March 2013, ApplyKit has already helped thousands of students around the world manage the application process. | Seed / Sep 12, 2013 | ||
| PageScience has evolved as a source for cookieless page-level scoring and targeting. It pioneered this capability in the healthcare industry 4 years ago and have expanded to other ad categories. Its integration with Appnexus enables the delivery of high-performing pages at a vast scale as they become available. | $515K / Seed / Aug 29, 2013 | ||
| Raven360 empowers enterprises of all sizes to control intellectual property and other valuable content as it is shared externally. | Series A / Jun 06, 2013 | ||
| ZetrOZ is revolutionizing the ultrasound industry by introducing proprietary generator technology that is more efficient, more portable, and more economically viable than any ultrasound generator presently available. | Series A / Apr 21, 2013 | ||
| Respiratory Motion has a wide variety of patient populations and environments to assess respiratory function and provide early warning of respiratory collapse. It is a commercial-stage medical device company that specializes in the fields of medical devices, clinical evaluation and testing, manufacturing, and respiratory monitoring. | Convertible Note / Mar 01, 2013 | ||
| InfoBionic transforms the efficiency and the economics of ambulatory remote patient monitoring processes and cardiac diagnostic services by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. It has developed the MoMe System, a remote patient monitoring platform initially focused on cardiacarrhythmia detection, to improve clinical efficiency and patient care with any time, anywhere access to patient data. | $969K / Seed / Dec 20, 2012 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Oleg Uritsky invest in?
Oleg Uritsky invests primarily in Biotechnology, Medical Device and Software startups, most often at Seed and Funding Round stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Oleg Uritsky invest in?
Oleg Uritsky typically joins rounds of $515k–$1.7M at Seed. These are whole funding-round sizes, not Oleg Uritsky's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Oleg Uritsky took part in.
How do I contact Oleg Uritsky?
Public channels for Oleg Uritsky include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Oleg Uritsky last invest?
The most recent investment recorded for Oleg Uritsky closed in Apr 2014. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
